A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Treatment-Naive and IFN Experienced Subjects With Genotype 1 Chronic Hepatitis C
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary) ; Asunaprevir; Daclatasvir
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms UNITY 3
- Sponsors Bristol-Myers K.K.; Bristol-Myers Squibb
- 03 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 May 2015 Planned End Date changed from 1 Sep 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 09 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.